

Medical Device Regulatory Reliance

Benefits and Opportunities

March 10, 2025




Overview



Observations from IMDRF 25 Joint
IMDRF-Industry Workshop on “Reliance”
March 2024



The Value of a Reliance Playbook &
Foundational Principles



Looking Ahead



“Benefits and Opportunities of Medical Device Regulatory Reliance”

11 March 2024 White Paper

Pre Market

Post Market

Speeds access to patients of safe, effective, high-quality, innovative medical devices across the Total Product Life Cycle

Allows for faster identification of and communication about potential safety issues

Regulatory authorities maintain sovereignty and their own decision – making authority

Allows for appropriate allocation of local resources for post market activities

Allows for knowledge sharing among regulatory authorities and reallocation of resources within a given regulatory authority without decrease in regulatory requirements

Use of internationally harmonized standards (e.g., ISO 13485) and IMDRF Technical Documents (e.g., IMDRF/AET WG/N43: Terminologies for Adverse Event Reporting (AER): Terms, Terminology and Codes); convergence to a common definition of significant and non-significant change

Trust, communication, clarity and transparency among regulatory authorities relying on one another is critical for successful reliance

Trust, communication, clarity and transparency among regulatory authorities relying on one another is critical for successful reliance

While convergence of regulatory frameworks enhances reliance, it is not a prerequisite for reliance

The MDSAP provides a success story of reliance for regulatory audits of manufacturers.



Outcomes: IMDRF 25 Joint Workshop on Reliance - March 2024

IMDRF plays a critical role in bringing stakeholders together to share experiences and build trust.

Future work for IMDRF to further reliance:

- Publication of a **“Reliance Playbook”** that includes general strategies, practical examples and recommendations for implementing a reliance program;
- Identification of which regulators within IMDRF have implemented reliance practices; and
- Training to support adoption of IMDRF technical documents and convergence of regulatory requirements.





The Value of a Reliance Playbook



Promote Understanding

- Educate stakeholders about the opportunities and benefits of the implementation of reliance



Share Best Practices

- Provides strategies and practical examples of successful reliance models
- Recommendations of how reliance can be implemented in different regulatory environments, showcase flexibility
- Use of consensus standards to support reliance across the Total Product Life Cycle
- Examples of how to determine product “sameness”, despite differences in classification, product names



Encourage Collaboration

- Foster collaboration and trust among regulatory authorities by sharing knowledge and experiences
- Regulatory authorities maintain sovereignty on their own decision-making



RELIANCE

Foundational Principles



Founded in Law/ Country Legislation

- Transparent
- Public Comment



Medical Devices & In Vitro Diagnostics

- Not included
under Medicines &
Vaccines



Definitions & Criteria

- WHO Good Reliance
Practices Guidance
- WHO Global Model
Regulatory Frameworks



A Challenge: Determining Product “Sameness”



Product Name Variations:

Product names may include or exclude codes/models, which can vary by region for traceability purposes.



Risk Classification Misalignment:

Differences in risk classification across regions.



Intended Use Discrepancies:

Variations in the stated intended use of products

A Solution: WHO Definition of Product “Sameness”

“...two products have identical essential characteristics...”¹

- **All relevant aspects** of medical devices and IVDs to be considered
- **Results of supporting studies of safety & performance**, indications, conditions of use
- **Potential, justified differences to be assessed** by the manufacturer (and the relying NRA)
- **Essential role of the manufacturer** to confirm the sameness of a product and to provide the same documentation to different NRAs

Product “Sameness”






Opportunities Realized through Reliance



Faster Access to
Safe, Quality
Innovations



Efficiency and
Resource
Optimization



Enhanced decision-
making, retain
sovereignty



Build trust and
harmonization





Looking Ahead...

IMDRF Management Committee Recommendations

- Complete and refine the Reliance Playbook to:
 - Include practical information and real-world examples to help operationalize reliance
 - Ensure it meets the needs of regulatory authorities
 - Allow for flexibility
- Adopt WHO definitions for Reliance and Product Sameness¹
- Reinforce Good Regulatory Practices and use of the WHO Good Reliance Practices¹





Looking Ahead...

Industry Recommendations

- Support regulators as they operationalize reliance pathways and with determination of product sameness
- Share examples of reliance in practice by regulatory authorities
- **Use the Reliance pathway!**





Thank you!

Any Questions?

Renata Brandao, Director Regulatory Affairs, Abbott
Diane Wurzbarger, VP Regulatory, Quality and Global Policy, GE HealthCare
On behalf of GMTA & DITTA